#9 Millennium Pharma
40 Landsdowne St.
Cambridge, MA 02139
Tel: (800) 390-5663
Fax: (617) 374-7788
www.mlnm.com
| Headcount |
1,142 |
|
| Year Established |
1993 |
|
| Biopharma Revenues |
$316 |
-9% |
| Total Revenues |
$558 |
+25% |
| Royalty Revenues |
$205 |
+107% |
| Net Loss |
-$198 |
|
| R&D Budget |
$342 |
-15% |
| Drugs Approved/Launched |
| Drug |
Indication |
| velcade |
second line multiple myeloma
|
Drugs Pending Approval
|
| Drug |
Indication |
| velcade |
relapsed, refractory mantle cell lymphoma
|
| Drugs in Phase IIb and Beyond |
| Drug |
Indication
|
velcade
|
follicular/mantle cell/marg. zn., NSCLC / BAC
|
| mln0518 |
acute myelogenous leukemia |
mln1202
|
multiple sclerosis, atherosclerosis
|
Early Research Projects
|
| Drug |
Indication |
mln8054
|
solid tumors |
| velcade |
other tumors |
mln3897
|
rheumatoid arthritis |
| mln3701 |
rheumatoid arthritis |
mln0002
|
ulcerative colitis |
mln0415
|
inflammatory and autoimmune diseases |
Top Selling Drugs
|
| Drug |
Indication
|
Sales
|
(+/-%)
|
velcade
|
multiple myeloma |
$194 |
+34% |
| integrilin |
cardiovascular disease |
$124 |
-40% |
Account for 100% of total biopharma sales, same as in 2004.
|
Magazine
